Chimeric Transgenic Nematodes for Human Variant Phenotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transgenic animal models, such as C. elegans and zebrafish, are inefficient for accurately assessing the functional consequences of human genomic variants, particularly missense changes, due to suboptimal transgenic compositions and high costs, limiting their ability to handle the high throughput needed for clinical variant analysis and drug discovery.
Innovation Solution
Development of a transgenic animal platform using chimeric heterologous genes, where human exon coding sequences are paired with host animal intron sequences to replace native orthologs, optimizing expression and restoring function, allowing for high-throughput phenotyping and drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional transgenic animal models (C. elegans, zebrafish) are used to assess human genomic variants, then functional assessment capability is provided, but accuracy and efficiency are insufficient due to suboptimal transgenic compositions
Solution Approach 1:
The patent applies local quality by creating chimeric genes where only specific portions (exons) are from human origin while intronic and regulatory regions are from the host organism. This localized human sequence insertion into specific genomic contexts enables accurate functional assessment of human variants while maintaining host organism efficiency and throughput.
Solution Approach 2:
The invention uses composite genetic structures combining human exonic sequences with host intronic and regulatory sequences to create chimeric transgenic constructs. This composite approach leverages the functional relevance of human coding sequences while utilizing the efficient expression and phenotypic assessment capabilities of the host organism system.
2Reliability
If transgenic animal models are used for clinical variant analysis, then functional insight is gained, but costs are high and throughput is limited
Solution Approach 1:
The patent creates simplified copies of human genes adapted for host organism expression by replacing human intronic and regulatory sequences with host-equivalent sequences. These chimeric copies maintain the essential functional information of human variants while enabling efficient generation and high-throughput analysis in the host system, reducing both cost and time requirements.
Solution Approach 2:
The invention changes the genomic context parameters of human genes by modifying intronic and regulatory regions to match host organism characteristics while preserving exonic sequences. This parameter optimization enables the transgenic system to efficiently process and phenotypically assess multiple human variants at lower cost and higher throughput while maintaining functional reliability.
3Adaptability or versatility
If human exon sequences are inserted into host animal genomes, then functional assessment of human variants is enabled, but expression efficiency may be suboptimal without optimization
Solution Approach 1:
The patent segments human genes into exonic and intronic/regulatory components, retaining only the essential exonic coding sequences while replacing the rest with host organism sequences. This segmentation enables precise control over expression efficiency through host-optimized regulatory elements while preserving the functional information needed for human variant assessment.
Solution Approach 2:
The chimeric gene structure acts as an intermediary between human and host organism genomic systems. Human exonic sequences provide the functional information to be assessed, while host intronic and regulatory sequences mediate efficient expression and proper genomic integration, bridging the compatibility gap between human gene sequences and host expression machinery.
Data Source
AI summary
The present disclosure provides transgenic nematode systems for assessing function of heterologous genes, their variants and drug discovery. The transgenic nematodes contain a heterologous gene that is inserted via homologous recombination at the native locus replacing and removing the nematode ortholog, wherein expression of the heterologous gene rescues function of the removed nematode ortholog and a transgenic control animal is provided. The heterologous gene may be further modified to provide a variant, such as a human clinical variant, whereby a transgenic test animal is provided. Those transgenic test animals are used in methods to assess function of the heterologous variant and drug screens to find therapeutic candidates reversing deviant activity back to wildtype.